Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population

BACKGROUND: Dalbavancin is a lipoglycopeptide with activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), and is FDA-approved as a single- or two-dose regimen. The objective of this study was to assess efficacy and safety of dal...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Georgiades, Benjamin, Rappo, Urania, Gonzalez, Pedro L, McGregor, Jennifer S, Chen, Jie, McCarthy, Matthew
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631734/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.114
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires